Literature DB >> 26484139

Expression-profiling of apoptosis induced by ablation of the long ncRNA TRPM2-AS in prostate cancer cell.

Giovanni Lavorgna1, Fulvio Chiacchiera2, Alberto Briganti1, Francesco Montorsi1, Diego Pasini2, Andrea Salonia3.   

Abstract

We recently identified the long non-coding RNA (ncRNA) TRPM2-AS as a key regulator of survival in prostate cancer [1]. This essential role, coupled to the TRPM2-AS low-expression levels in healthy tissues, makes this ncRNA a suitable therapeutic target for further clinical studies. To get insights into the survival mechanism controlled by this molecule, we ablated its expression in prostate cancer cells and performed a genome-wide analysis of the transcripts differentially regulated in dying cells. Here, we describe in detail the experimental system, methods and quality control for the generation of the microarray data associated with our recent publication [1]. The data are related to [1]. Data have been deposited to the Gene Expression Omnibus (GEO) database repository with the dataset identifier GSE40687.

Entities:  

Keywords:  Apoptosis; Ion channel; Microarray; Prostate cancer; ncRNA

Year:  2014        PMID: 26484139      PMCID: PMC4535459          DOI: 10.1016/j.gdata.2014.10.020

Source DB:  PubMed          Journal:  Genom Data        ISSN: 2213-5960


Direct link to the deposited data

Microarray data is deposited at the NCBI Gene Expression Omnibus (GEO) database under GEO Series and is available at the following link: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE40687.

Experimental design, materials and methods

Cell line

The human, androgen-independent prostate cancer cell line PC3 was obtained from ATCC (CRL-1435, ATCC).

RNA interference

During an in-silico search for antisense transcripts [2], [3], [4], we have identified TRPM2-AS as antisense transcript in respect to TRPM2 gene, which encodes an oxidative stress-activated ion channel [5]. This long ncRNA is overexpressed in several tumor types [1], [4] and its knock-out leads to massive apoptosis of PC3 and DU145 prostate cancer cells [1]. To gain a molecular understanding of the mechanisms by which TRPM2-AS maintains cell survival in prostate cancer cells, PC3 cells were transfected for 48 h either with a non-specific siRNA or with a siRNA ablating TRPM2-AS RNA.

Microarray and quality control

To identify the transcripts that are regulated by TRPM2-AS, we isolated total RNA from four samples (two technical replicates) of PC3 cell lines that had been transfected with the control siRNA or with the experimental siRNA targeting TRPM2-AS expression. The quantity and quality of the RNA samples was measured and assessed by a NanoDrop spectrophotometer and Agilent 2100 Bioanalyzer (Agilent Technologies). Illumina microarray analysis was performed using the Illumina HumanHT-12 V3.0 expression beadchip. Quantitative real-time PCR (qRT-PCR) was used to check the microarray data, analyzing transcript levels that changed in both directions. In particular segments corresponding to the following transcripts were amplified: AURKA, PABPC4, E2F2, CDC20, FRAP1, BIRC5, CDC25B, CDKN1A, IL1B, IL8. Results, shown in Fig. 1, indicated that while, due to the large dynamic range of qRT-PCR [6], microarray data were mostly slightly compressed, there was an excellent qualitative correlation among the two techniques (correlation coefficient: 0.97), thereby validating the microarray experiment.
Fig. 1

Validation of microarray data by qRT-PCR. Ten transcripts were quantified by qRT-PCR both in control and in TRPM2-AS KO PC3 cells. The resulting expression fold change is plotted against the expression fold change obtained from the Illumina HumanHT-12 V3.0 microarray data. A correlation coefficient of 0.97 was found between the two datasets.

Discussion

We report here a dataset composed of microarray gene expression profiling of TRPM2-AS-regulated transcripts. With this experiment, we were able to show that TRPM2-AS coordinates the expression of a large number of genes involved in controlling the survival, the unfolded protein response (UPR) response and the cell-cycle progression in prostate cancer cells. Moreover, targets of existing drugs and treatments were found to be consistently regulated by TRPM2-AS KO, underlying the clinical relevance of this long ncRNA as a novel therapeutic target. According to the dual role of the UPR in promoting cell survival or commitment to programmed cell death [7], several pro-survival molecules and known oncological targets, including the chaperonin HSP90B1 and the oncogenes FYN and AKT1, were also induced by TRPM2-AS KO, suggesting that the dataset as a whole would be particularly valuable for identifying new molecular targets and underlying mechanisms.
Specifications
Organism/cell line/tissueHomo sapiens
SexMale
Sequencer or array typeIllumina HumanHT-12 V3.0 expression beadchip
Data formatMicroarray raw and normalized data: TXT files
Experimental factorsPC3 cells without or with TRPM2-AS expression
Experimental featuresMicroarray gene expression profiling to identify transcripts that are regulated by TRPM2-AS
ConsentN/A
Sample source locationN/A
  7 in total

Review 1.  Real-time PCR for mRNA quantitation.

Authors:  Marisa L Wong; Juan F Medrano
Journal:  Biotechniques       Date:  2005-07       Impact factor: 1.993

Review 2.  The TRPM2 ion channel, an oxidative stress and metabolic sensor regulating innate immunity and inflammation.

Authors:  Heather Knowles; Yuan Li; Anne-Laure Perraud
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

3.  Endoplasmic reticulum stress response in cancer: molecular mechanism and therapeutic potential.

Authors:  Guohui Wang; Zeng-Quan Yang; Kezhong Zhang
Journal:  Am J Transl Res       Date:  2010-01-01       Impact factor: 4.060

4.  Identification of novel sense and antisense transcription at the TRPM2 locus in cancer.

Authors:  Ugo Orfanelli; Ann-Kathrin Wenke; Claudio Doglioni; Vincenzo Russo; Anja Katrin Bosserhoff; Giovanni Lavorgna
Journal:  Cell Res       Date:  2008-11       Impact factor: 25.617

5.  Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer.

Authors:  U Orfanelli; E Jachetti; F Chiacchiera; M Grioni; P Brambilla; A Briganti; M Freschi; F Martinelli-Boneschi; C Doglioni; F Montorsi; M Bellone; G Casari; D Pasini; G Lavorgna
Journal:  Oncogene       Date:  2014-06-16       Impact factor: 9.867

Review 6.  In search of antisense.

Authors:  Giovanni Lavorgna; Dvir Dahary; Ben Lehner; Rotem Sorek; Christopher M Sanderson; Giorgio Casari
Journal:  Trends Biochem Sci       Date:  2004-02       Impact factor: 13.807

7.  AntiHunter 2.0: increased speed and sensitivity in searching BLAST output for EST antisense transcripts.

Authors:  Giovanni Lavorgna; Riccardo Triunfo; Federico Santoni; Ugo Orfanelli; Sara Noci; Alessandro Bulfone; Gianluigi Zanetti; Giorgio Casari
Journal:  Nucleic Acids Res       Date:  2005-07-01       Impact factor: 16.971

  7 in total
  8 in total

1.  Identification of lncRNA TRPM2-AS/miR-140-3p/PYCR1 axis's proliferates and anti-apoptotic effect on breast cancer using co-expression network analysis.

Authors:  Tong Sun; Yan Song; Hong Yu; Xiao Luo
Journal:  Cancer Biol Ther       Date:  2019-02-27       Impact factor: 4.742

Review 2.  MicroRNAs: master regulators in host-parasitic protist interactions.

Authors:  Maura Rojas-Pirela; Diego Andrade-Alviárez; Lisvaneth Medina; Christian Castillo; Ana Liempi; Jesús Guerrero-Muñoz; Yessica Ortega; Juan Diego Maya; Verónica Rojas; Wilfredo Quiñones; Paul A Michels; Ulrike Kemmerling
Journal:  Open Biol       Date:  2022-06-15       Impact factor: 7.124

3.  TRPM2-AS promotes the malignancy of osteosarcoma cells by targeting miR-15b-5p/PPM1D axis.

Authors:  Yingchun Cai; Yudan Yang; Xudong Zhang; Qingqing Ma; Mengyi Li
Journal:  Cell Cycle       Date:  2022-01-31       Impact factor: 5.173

Review 4.  Carcinogenesis in prostate cancer: The role of long non-coding RNAs.

Authors:  John Aird; Anne-Marie Baird; Marvin C J Lim; Ray McDermott; Stephen P Finn; Steven G Gray
Journal:  Noncoding RNA Res       Date:  2018-02-01

Review 5.  Long non-coding RNAs and prostate cancer.

Authors:  Aya Misawa; Ken-Ichi Takayama; Satoshi Inoue
Journal:  Cancer Sci       Date:  2017-09-05       Impact factor: 6.716

Review 6.  The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer.

Authors:  Cristian Arriaga-Canon; Inti Alberto De La Rosa-Velázquez; Rodrigo González-Barrios; Rogelio Montiel-Manríquez; Diego Oliva-Rico; Francisco Jiménez-Trejo; Carlo Cortés-González; Luis A Herrera
Journal:  Oncotarget       Date:  2018-04-17

Review 7.  Roles of NAD+ and Its Metabolites Regulated Calcium Channels in Cancer.

Authors:  Peilin Yu; Xiaobo Cai; Yan Liang; Mingxiang Wang; Wei Yang
Journal:  Molecules       Date:  2020-10-20       Impact factor: 4.411

8.  Long non-coding RNA TRPM2-AS regulates microRNA miR-138-5p and PLAU (Plasminogen Activator, Urokinase) to promote the progression of gastric adenocarcinoma.

Authors:  Jun Sun; Fang Zhou; Juan Xue; Chunyan Ji; Yinzong Qu; Yuwei Pan
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.